Plain-English translation of NCT07466160 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1/2 โ A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a combination of two new medications called and , given either alone together or alongside chemotherapy, to see if they can help people with advanced solid tumors. Researchers want to understand how safe the medication is, how your body processes it, and whether it can shrink or slow cancer growth.
Many people with advanced cancers stop responding to standard treatments or cannot tolerate them. This trial exists to explore whether this new combination approach might offer another option for patients who have limited choices.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would receive intravenous infusions of the medication at a clinic, either alone or combined with chemotherapy, depending on which group you're assigned to. The trial has two phases: in Phase 1b, doctors test different doses to find the safest level, and in Phase 2, more patients receive the best dose identified. You would have regular visits for blood tests, imaging scans, and check-ins to monitor how you're responding and watch for side effects.
AI-generated summary from trial data ยท Sep 2, 2026 ยท Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Enrollment target
~280 participants
Started
February 2026
Primary completion
December 2027
Age range
18 Years โ 75 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Shun Lu, Doctor
Mabwell (Shanghai) Bioscience Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.